Biodeal Pharma raises ₹385 cr growth investment from RMB Capitalworks

Biodeal Pharmaceuticals announced a growth investment of ₹385 crore from RMB Capitalworks, a joint venture between Rand Merchant Bank and Capitalworks Group. The investment will support the company’s next phase of expansion across specialty pharmaceuticals, manufacturing capabilities, and regulated markets.

Biodeal has built more than two decades of leadership in nasal drug delivery, supported by integrated pharma development and manufacturing capabilities. The investment will support Biodeal’s next phase of expansion, strengthening its positions across Asian markets while accelerating growth across CIS, LATAM, Africa and Europe.

“This investment represents much more than capital – it is a strong endorsement of the platform we have built over the past two decades. At Biodeal, we have consistently focused on creating differentiated capabilities in specialty pharmaceuticals, anchored by leadership in nasal drug delivery and a relentless focus on quality and manufacturing excellence. This milestone reflects the strength of what we’ve built and the scale of what lies ahead. We are delighted to welcome RMB Capitalworks as a long-term strategic partner – we chose to partner with them because of the value they bring beyond capital, and their operational expertise, governance philosophy and growth mindset align closely with our vision as we build a globally competitive specialty pharmaceutical company and advance on our path towards a planned public listing,” said Anurag Kumar, CMD, Biodeal Pharmaceuticals.

“We love founders passionate about building enduring businesses, and we saw that exact fire in Anurag. We work closely with founders to co-create solutions that unlock personal value and provide the long-term financial stability needed to execute ambitious growth plans. Healthcare is a core focus for us, and Biodeal fits our thesis of a differentiated player primed for rapid growth. We are proud to act as true partners, working alongside the Biodeal team to strengthen governance, accelerate expansion, and build a leading pharmaceutical powerhouse,” said Anshuman Malur, Managing Partner, RMB Capitalworks.

A company release informed, “Biodeal has delivered consistent profitable growth over the past five years, with FY26 revenue estimated to grow 60%+ year-on-year and EBITDA margins expanding further. The company is entering its next phase of growth with a clear ambition; to strengthen its position as a globally trusted specialty pharma partner while advancing confidently on its path towards a planned public listing.”